BLU-5937, A Potent and Selective P2X3 Antagonist, For the Treatment of Chronic Itch: Evidence from Pre-Clinical Studies

被引：1
|
作者：
Chauret, N. [1 ]
Ase, A. R. [2 ]
Seguela, P. [2 ]
Liu, X. Y. [3 ]
Matzouranis, T. [1 ]
Garceau, D. [1 ]
机构：
[1] Bellus Hlth Inc, Laval, PQ, Canada
[2] Mc Gill, MNI, Montreal, PQ, Canada
[3] Univ Washington, St Louis, MO USA
来源：
JOURNAL OF INVESTIGATIVE DERMATOLOGY | 2019年 / 139卷 / 09期
关键词：
D O I：
10.1016/j.jid.2019.07.110
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
106
引用
收藏
页码：S232 / S232
页数：1
相关论文
共 50 条
  • [21] The Treatment of Chronic Cough in Idiopathic Pulmonary Fibrosis Patients with Gefapixant, a P2x3 Receptor Antagonist
    Martinez, F. J.
    Afzal, A.
    Kitt, M. M.
    Ford, A.
    Li, J. J.
    Li, Y.
    Smith, J.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2019, 199
  • [22] Discovery and optimization of RO-85, a novel drug-like, potent, and selective P2X3 receptor antagonist
    Brotherton-Pleiss, Christine E.
    Dillon, Michael P.
    Ford, Anthony P. D. W.
    Gever, Joel R.
    Carter, David S.
    Gleason, Shelley K.
    Lin, Clara J.
    Moore, Amy G.
    Thompson, Anthony W.
    Villa, Marzia
    Zhai, Yansheng
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2010, 20 (03) : 1031 - 1036
  • [23] Preclinical and Clinical Pharmacokinetics and Bioavailability in Healthy Volunteers of a Novel Formulation of the Selective P2X3 Receptor Antagonist Eliapixant
    Klaus Francke
    Niladri Chattopadhyay
    Stefan Klein
    Antje Rottmann
    Dennis Krickau
    Jeroen van de Wetering
    Christian Friedrich
    European Journal of Drug Metabolism and Pharmacokinetics, 2023, 48 : 75 - 87
  • [24] Preclinical and Clinical Pharmacokinetics and Bioavailability in Healthy Volunteers of a Novel Formulation of the Selective P2X3 Receptor Antagonist Eliapixant
    Francke, Klaus
    Chattopadhyay, Niladri
    Klein, Stefan
    Rottmann, Antje
    Krickau, Dennis
    van de Wetering, Jeroen
    Friedrich, Christian
    EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 2023, 48 (01) : 75 - 87
  • [25] Baseline patient burden in chronic cough from a Phase 2b clinical trial of gefapixant, a P2X3 receptor antagonist
    Birring, Surinder S.
    Mcgarvey, Lorcan
    Smith, Jaclyn
    Morice, Alyn
    Sher, Mandel
    Wu, Wen-Chi
    Xu, Zhi Jin
    Nguyen, Allison M.
    Schelfhout, Jonathan
    Muccino, David
    EUROPEAN RESPIRATORY JOURNAL, 2019, 54
  • [26] Model-based Dose Selection for Phase 3 Trials of the Selective P2X3 Antagonist Camlipixant in efractory Chronic Cough
    Chauret, N.
    Garin, M.
    Harvey, L.
    Gahir, S.
    Yang, T.
    Garceau, D.
    Bonuccelli, C. M.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2023, 207
  • [27] A Phase 2 Dose-Escalation Study With Af-219, A P2x3 Antagonist For The Treatment Of Chronic Cough
    Smith, J. A.
    Kitt, M.
    Sher, M.
    Butera, P.
    Ford, A. P.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2016, 193
  • [28] Design and synthesis of potent and selective P2X3 receptor antagonists derived from PPADS as potential pain modulators
    Cho, Joong-Heui
    Jung, Kwan-Young
    Jung, Younghwan
    Kim, Mm Hye
    Ko, Hyojin
    Park, Chul-Seung
    Kim, Yong-Chul
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2013, 70 : 811 - 830
  • [29] Chronic administration of the selective P2X3, P2X2/3 receptor antagonist, A-317491, transiently attenuates cancer-induced bone pain in mice
    Hansen, Rikke Rie
    Nasser, Arafat
    Falk, Sarah
    Baldvinsson, Signe B.
    Ohlsson, Pernille H.
    Bahl, Justyna M. C.
    Jarvis, Michael F.
    Ding, Ming
    Heegaard, Anne-Marie
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2012, 688 (1-3) : 27 - 34
  • [30] TREATMENT OF REFRACTORY OR UNEXPLAINED CHRONIC COUGH WITH GEFAPIXANT, A P2X3 RECEPTOR ANTAGONIST, OVER 52 WEEKS IN TWO PHASE III CLINICAL TRIALS
    Dicpinigaitis, Peter
    Birring, Surinder
    Morice, Alyn
    Smith, Jaclyn
    Mcgarvey, Lorcan
    Pavord, Ian
    Nguyen, Allison
    Schelfhout, Jonathan
    Tzontcheva, Anjela
    Li, Qing
    Muccino, David
    La Rosa, Carmen
    CHEST, 2021, 160 (04) : 2361A - 2362A
12345